BioSpace News Archive

Have you ever heard the phrase, “worse than a root canal?” Chances are you have, but thanks likely to modern advancements in technology and the advanced training of root canal specialists known as endodontists, it turns out that cliché analogy may not ring as true as you think.

The nation’s top-ranked hospital for orthopedics announced a major new location opening in New York City in August 2019.

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies, today announces it has achieved two-thirds enrollment in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed MGMT-unmethylated GBM.

SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the 39th Annual Canaccord Genuity Global Growth Conference at The InterContinental Boston on Wednesday, August 7, 2019 at 5:00 p.m. ET.

Endo International plc (NASDAQ: ENDP) and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, are pleased to announce today that Endo International plc’s subsidiary Endo Ventures Limited has entered into definitive agreements with Helsinn

Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Christopher D.T. Guiffre, J.D., M.B.A., Chief Financial Officer and Chief Operating Officer, will present at the Canaccord Genuity 39th Annual Growth Conference in Boston on Wednesday, August 7 at 11:00 a.m. Eastern Tim

Axcella Health, (Nasdaq: AXLA) (“Axcella” or the “Company”), a biotechnology company pioneering the research and development of novel multifactorial interventions using novel compositions of endogenous metabolic modulators to address dysregulated metabolism and support health, announced the publication of data describing the safety, tolerability and impact of investigational product AXA2678 on short-term muscle disuse atrophy in young healthy men.

Findings validate the mechanism of action for the Company’s lead asset, BLD-2660

The share issue entails a dilution of approximately 9.3 percent of the number of shares and votes in the company.

This is CTD’s fourth year of supporting the conference with an unrestricted grant and in presenting on the company’s clinical program in Niemann-Pick Disease Type C (NPC).